Literature DB >> 29603370

Disease Modification for Parkinson's Disease: Axonal Regeneration and Trophic Factors.

Jeffrey H Kordower1,2, Robert E Burke3,4.   

Abstract

Disease modification and structural neuroprotection have been the holy grail for Parkinson's disease (PD) experimental therapeutics. Theoretically, there are a number of ways to implement such therapeutics, but to date all have failed. This review examines the potential of axonal regeneration and trophic factor delivery for the nigrostriatal system as 2 such approaches that historically have initiated much excitement. However, we conclude this discussion with the following question: has science passed these approaches by?
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Disease modification; Trophic Factors; axons

Mesh：

Substances：

Year:  2018        PMID： 29603370     DOI： 10.1002/mds.27383

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  10 in total

Review 1.  Blood-brain barrier opening with focused ultrasound in experimental models of Parkinson's disease.

Authors:  Maria Eleni Karakatsani; Javier Blesa; Elisa Evgenia Konofagou
Journal:  Mov Disord       Date:  2019-07-30       Impact factor: 10.338

Review 2.  Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2020-01-28       Impact factor: 3.575

Review 3.  Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier?

Authors:  Richard J Price; Delaney G Fisher; Jung Soo Suk; Justin Hanes; Han Seok Ko; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2019-03-25       Impact factor: 10.338

4.  Disruption of mitochondrial complex I induces progressive parkinsonism.

Authors:  Patricia González-Rodríguez; Enrico Zampese; Kristen A Stout; Jaime N Guzman; Ema Ilijic; Ben Yang; Tatiana Tkatch; Mihaela A Stavarache; David L Wokosin; Lin Gao; Michael G Kaplitt; José López-Barneo; Paul T Schumacker; D James Surmeier
Journal:  Nature       Date:  2021-11-03       Impact factor: 69.504

5.  Direct delivery of an investigational cell therapy in patients with Parkinson's disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design.

Authors:  Jorge E Quintero; John T Slevin; Julie A Gurwell; Christopher J McLouth; Riham El Khouli; Monica J Chau; Zain Guduru; Greg A Gerhardt; Craig G van Horne
Journal:  BMJ Neurol Open       Date:  2022-07-14

6.  Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons.

Authors:  Steven M Graves; Sarah E Schwarzschild; Rex A Tai; Yu Chen; D James Surmeier
Journal:  Neurobiol Dis       Date:  2021-05-31       Impact factor: 5.996

7.  α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo.

Authors:  Victor S Van Laar; Jianming Chen; Alevtina D Zharikov; Qing Bai; Roberto Di Maio; April A Dukes; Teresa G Hastings; Simon C Watkins; J Timothy Greenamyre; Claudette M St Croix; Edward A Burton
Journal:  Redox Biol       Date:  2020-08-22       Impact factor: 11.799

8.  Homing of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) Labeled Adipose-Derived Stem Cells by Magnetic Attraction in a Rat Model of Parkinson's Disease.

Authors:  Ardeshir Moayeri; Marzieh Darvishi; Mansour Amraei
Journal:  Int J Nanomedicine       Date:  2020-02-26

9.  Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans.

Authors:  Kevin S Chen; Krystal Menezes; Suneil K Kalia; Lorraine V Kalia; Jarlath B Rodgers; Darren M O'Hara; Nhat Tran; Kazuko Fujisawa; Seiya Ishikura; Shahin Khodaei; Hien Chau; Anna Cranston; Minesh Kapadia; Grishma Pawar; Susan Ping; Aldis Krizus; Alix Lacoste; Scott Spangler; Naomi P Visanji; Connie Marras; Nour K Majbour; Omar M A El-Agnaf; Andres M Lozano; Joseph Culotti; Satoshi Suo; William S Ryu
Journal:  Mol Neurodegener       Date:  2021-11-12       Impact factor: 14.195

Review 10.  Linking α-synuclein-induced synaptopathy and neural network dysfunction in early Parkinson's disease.

Authors:  Aishwarya S Kulkarni; Matthew R Burns; Patrik Brundin; Daniel W Wesson
Journal:  Brain Commun       Date:  2022-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.